Researchers at the Weizmann Institute of Science, led by Prof. Atan Gross, explore a novel approach to combating obesity by targeting a mitochondrial protein called MTCH2, nicknamed "Mitch." Originally discovered through a serendipitous experiment, the team found that silencing Mitch in mice not only prevented fat accumulation but also enhanced muscle endurance and metabolic rate. These mice became effectively immune to obesity and showed improved heart function and physical performance.
The key to these effects lies in Mitch’s role in regulating mitochondrial fusion—the process by which mitochondria merge to form efficient energy-producing networks. When Mitch is silenced, mitochondria remain fragmented and less efficient, forcing cells to burn more energy to meet their needs. This inefficiency paradoxically leads to increased energy expenditure, which in turn reduces fat storage and boosts muscle performance.
Building on these findings, the team extended their research to human cells. Using genetic engineering, they deleted Mitch in fat cells and observed a collapse of the mitochondrial network. This led to a permanent state of energy deprivation in the cells, which responded by increasing the breakdown of fats and carbohydrates while also inhibiting the formation of new fat cells. These results suggest that Mitch plays a central role in energy balance and fat metabolism in humans as well.
The implications of this research are significant. Unlike current weight-loss drugs that often reduce muscle mass, targeting Mitch could offer a dual benefit: reducing fat while preserving or even enhancing muscle function. This opens up promising avenues for developing new treatments for obesity, metabolic disorders, and possibly even enhancing athletic performance or recovery in clinical settings.
A version of this article was originally published at Weizmann Wonder Wander.
